Form 4: QuidelOrtho CFO Reports RSU Vesting, Tax-Related Sale

QuidelOrtho's Chief Financial Officer, Joseph M. Busky, reported the vesting of restricted stock units and a subsequent tax-related sale of shares.

Summary

• Joseph M. Busky, Chief Financial Officer of QuidelOrtho Corp (QDEL), reported changes in his beneficial ownership of common stock.
• On January 29, 2026, 8,425 shares of common stock were acquired at a price of $0, reflecting the release of previously reported restricted stock units (RSUs).
• Concurrently, 2,602 shares of common stock were disposed of at a price of $27.41 per share on January 29, 2026, to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Busky directly beneficially owns 37,250 shares of common stock.
• Additionally, 6,920 shares of common stock are indirectly beneficially owned by a trust.
• Mr. Busky also holds 16,851 derivative securities in the form of Restricted Stock Units, with future vesting dates.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The vesting of RSUs is a positive for the executive, representing earned compensation, while the tax-related sale is a standard, non-discretionary event that does not reflect a change in company fundamentals.

Positives

• The vesting of 8,425 restricted stock units represents a conversion of equity awards into common stock for the Chief Financial Officer, indicating a realization of compensation.

Negatives

• A disposition of 2,602 shares occurred to cover tax withholding obligations, which reduces the direct beneficial ownership of the Chief Financial Officer.

Future Outlook

Future vesting events for the Chief Financial Officer's restricted stock units are scheduled for January 29, 2027 (8,425 shares) and January 29, 2028 (8,426 shares).

Industry Context

StockSavvy.ai notes that routine insider transactions like RSU vesting and tax-related sales are common and typically do not signal major shifts in company strategy or performance, but rather reflect standard executive compensation practices within the biotechnology and diagnostics industry.

Comparison to Industry Standards

• StockSavvy.ai observes that RSU vesting and subsequent tax-related sales are standard practice across publicly traded companies, aligning with typical executive compensation structures in the healthcare and diagnostics sectors. This transaction is consistent with how executives at comparable companies like Danaher Corporation or Thermo Fisher Scientific manage their equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine insider compensation event, not indicative of operational changes or strategic shifts.
• Employees: No direct impact mentioned.

Next Steps

• 8,425 restricted stock units are scheduled to vest on January 29, 2027.
• 8,426 restricted stock units are scheduled to vest on January 29, 2028.

Key Dates

Recommendation

This Form 4 reports routine RSU vesting and a tax-related share disposition by the CFO. Such transactions are standard for executive compensation and do not provide new fundamental insights into QuidelOrtho's operational performance or strategic direction, thus warranting a hold recommendation.

Keywords

QuidelOrtho, QDEL, Form 4, Insider Transaction, Restricted Stock Units, RSU, Beneficial Ownership, CFO, Joseph M. Busky